Cargando…

Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial

BACKGROUND: COVID-19 is associated with inflammation and an increased risk of thromboembolic complications. Prophylactic doses of low-molecular-weight heparin have been used in hospitalised and non-critically ill patients with COVID-19. We aimed to evaluate the efficacy and safety of prophylactic lo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cools, Frank, Virdone, Saverio, Sawhney, Jitendra, Lopes, Renato D, Jacobson, Barry, Arcelus, Juan I, Hobbs, F D Richard, Gibbs, Harry, Himmelreich, Jelle C L, MacCallum, Peter, Schellong, Sebastian, Haas, Sylvia, Turpie, Alexander G G, Ageno, Walter, Rocha, Ana Thereza, Kayani, Gloria, Pieper, Karen, Kakkar, Ajay K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243570/ https://www.ncbi.nlm.nih.gov/pubmed/35779560 http://dx.doi.org/10.1016/S2352-3026(22)00173-9

Ejemplares similares

Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD‐VTE
por: Cohen, Omri, et al.
Publicado: (2021)

On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease
por: Haas, Sylvia, et al.
Publicado: (2022)

Cost-effectiveness analysis of two thromboprophylactic strategies following major surgery
por: Ebm, C, et al.
Publicado: (2012)

IMPACT OF THROMBOPROPHYLACTIC STRATEGY ON BLEEDING RISK AMONG IN- AND OUTPATIENTS WITH COVID-19
por: Svet, Mark, et al.
Publicado: (2021)

Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients
por: Veeranki, S. Phani, et al.
Publicado: (2020)

Determinants and clinical outcomes of patients who refused anticoagulation: findings from the global GARFIELD-AF registry
por: Apenteng, Patricia, et al.
Publicado: (2023)

Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE
por: Jerjes-Sánchez, Carlos, et al.
Publicado: (2021)

Neuraxial and peripheral nerve blocks in patients taking anticoagulant or thromboprophylactic drugs: challenges and solutions
por: Li, Jinlei, et al.
Publicado: (2015)

Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease
por: Goto, Shinya, et al.
Publicado: (2020)

Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE
por: Ageno, Walter, et al.
Publicado: (2021)

Thromboprophylactic Efficacy and Safety of Anticoagulants After Arthroscopic Knee Surgery: A Systematic Review and Meta-Analysis
por: Yu, Yang, et al.
Publicado: (2019)

Real-World Management of Pharmacological Thromboprophylactic Strategies for COVID-19 Patients in Japan: From the CLOT-COVID Study
por: Hayashi, Hiroya, et al.
Publicado: (2022)

Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry
por: Fox, Keith A A, et al.
Publicado: (2022)

Two-year outcomes of UK patients newly diagnosed with atrial fibrillation: findings from the prospective observational cohort study GARFIELD-AF
por: Apenteng, Patricia N, et al.
Publicado: (2022)

Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis
por: van Husen, Georg, et al.
Publicado: (2022)

The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events
por: Atar, Dan, et al.
Publicado: (2020)

Guideline-directed medical therapies for comorbidities among patients with atrial fibrillation: results from GARFIELD-AF
por: Camm, Alan John, et al.
Publicado: (2023)

Arterial indications for the low molecular weight heparins
por: Ageno, Walter, et al.
Publicado: (2001)

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
por: Nichetti, Federico, et al.
Publicado: (2019)

Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF
por: Camm, Christian Fielder, et al.
Publicado: (2022)

Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry
por: Haas, Sylvia, et al.
Publicado: (2016)

GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation
por: Fox, Keith A A, et al.
Publicado: (2021)

Caring for the Unvaccinated
por: Parker, William F.
Publicado: (2022)

Validating risk models versus age alone for atrial fibrillation in a young Dutch population cohort: should atrial fibrillation risk prediction be expanded to younger community members?
por: Himmelreich, Jelle C L, et al.
Publicado: (2022)

Healthcare Resource Utilization in Patients with Newly Diagnosed Atrial Fibrillation: A Global Analysis from the GARFIELD-AF Registry
por: Mantovani, Lorenzo G., et al.
Publicado: (2023)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
por: Beyer-Westendorf, Jan, et al.
Publicado: (2019)

Effect of intermediate/high versus low dose heparin on the thromboembolic and hemorrhagic risk of unvaccinated COVID-19 patients in the emergency department
por: Marchioni, Claudia, et al.
Publicado: (2022)

Effect of heparin treatment on pulmonary embolism and in-hospital death in unvaccinated COVID-19 patients without overt deep vein thrombosis
por: Bais, Bruno, et al.
Publicado: (2022)

Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry
por: Goto, Shinya, et al.
Publicado: (2019)

Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD‐AF Registry
por: Cools, Frank, et al.
Publicado: (2021)

Managing Unvaccinated Staff
Publicado: (2022)

Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD‐AF
por: Ambrosio, Giuseppe, et al.
Publicado: (2021)

What’s the evidence for fining the unvaccinated?
por: Vogel, Lauren, et al.
Publicado: (2022)

Our Unvaccinated Population Steadily Increasing
Publicado: (1921)

Yellow Fever in an Unvaccinated Traveler to Peru
por: Winnicka, Lydia, et al.
Publicado: (2017)

Clinical Experiences for Unvaccinated Nursing Students
por: Alexander, Maryann
Publicado: (2021)

COVID-19: stigmatising the unvaccinated is not justified
por: Kampf, Günter
Publicado: (2021)

Comparative effectiveness of oral anticoagulants in everyday practice
por: Camm, A John, et al.
Publicado: (2021)

The Vaccinated and unvaccinated need to coexist with tolerance and respect
por: The Lancet Regional Health – Europe
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gajhdqlrvsdd8higf051egh5f7